Cidara Therapeutics, Inc. (CDTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CDTX POWR Grades
- CDTX scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.21% of US stocks.
- The strongest trend for CDTX is in Quality, which has been heading down over the past 160 days.
- CDTX ranks lowest in Momentum; there it ranks in the 4th percentile.
CDTX Stock Summary
- Of note is the ratio of Cidara Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 7.94% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for Cidara Therapeutics Inc comes in at 310.81%, a number that bests 97.4% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CDTX comes in at -76.53% -- higher than that of only 5.41% of stocks in our set.
- Stocks that are quantitatively similar to CDTX, based on their financial statements, market capitalization, and price volatility, are XCUR, CBIO, IVA, ZYME, and AFMD.
- Visit CDTX's SEC page to see the company's official filings. To visit the company's web site, go to www.cidara.com.
CDTX Valuation Summary
- In comparison to the median Healthcare stock, CDTX's EV/EBIT ratio is 104.78% lower, now standing at -1.4.
- CDTX's price/earnings ratio has moved up 14.8 over the prior 78 months.
- CDTX's price/earnings ratio has moved up 14.8 over the prior 78 months.
Below are key valuation metrics over time for CDTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CDTX | 2021-08-31 | 2.8 | 7.2 | -2.3 | -1.4 |
| CDTX | 2021-08-30 | 2.6 | 6.8 | -2.2 | -1.3 |
| CDTX | 2021-08-27 | 2.5 | 6.6 | -2.1 | -1.2 |
| CDTX | 2021-08-26 | 2.5 | 6.4 | -2.1 | -1.2 |
| CDTX | 2021-08-25 | 2.6 | 6.8 | -2.2 | -1.3 |
| CDTX | 2021-08-24 | 2.5 | 6.5 | -2.1 | -1.2 |
CDTX Growth Metrics
- Its 2 year price growth rate is now at -22.89%.
- The 5 year cash and equivalents growth rate now stands at 43.73%.
- Its 3 year price growth rate is now at -81.46%.
The table below shows CDTX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 49.572 | -25.232 | -42.467 |
| 2021-09-30 | 46.076 | -21.453 | -49.19 |
| 2021-06-30 | 41.416 | -23.564 | -48.739 |
| 2021-03-31 | 11.945 | -41.076 | -75.864 |
| 2020-12-31 | 12.067 | -54.411 | -74.873 |
| 2020-09-30 | 10.153 | -58.48 | -67.262 |
CDTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CDTX has a Quality Grade of B, ranking ahead of 87.28% of graded US stocks.
- CDTX's asset turnover comes in at 0.684 -- ranking 42nd of 682 Pharmaceutical Products stocks.
- VNRX, PBH, and NVS are the stocks whose asset turnover ratios are most correlated with CDTX.
The table below shows CDTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.684 | 1 | 2.529 |
| 2021-03-31 | 0.190 | 1 | 4.489 |
| 2020-12-31 | 0.171 | 1 | 6.027 |
| 2020-09-30 | 0.140 | 1 | 5.823 |
| 2020-06-30 | 0.348 | 1 | 4.233 |
| 2020-03-31 | 0.327 | 1 | 5.374 |
CDTX Price Target
For more insight on analysts targets of CDTX, see our CDTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $6.17 | Average Broker Recommendation | 1.36 (Strong Buy) |
CDTX Stock Price Chart Interactive Chart >
CDTX Price/Volume Stats
| Current price | $0.45 | 52-week high | $2.39 |
| Prev. close | $0.46 | 52-week low | $0.41 |
| Day low | $0.44 | Volume | 137,600 |
| Day high | $0.46 | Avg. volume | 302,635 |
| 50-day MA | $0.73 | Dividend yield | N/A |
| 200-day MA | $1.26 | Market Cap | 30.99M |
Cidara Therapeutics, Inc. (CDTX) Company Bio
Cidara Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. The company was founded in 2012 and is based in San Diego, California.
Latest CDTX News From Around the Web
Below are the latest news stories about Cidara Therapeutics Inc that investors may wish to consider to help them evaluate CDTX as an investment opportunity.
Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should KnowCidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
H.C. Wainwright Thinks Cidara Therapeutics’ Stock is Going to RecoverH.C. Wainwright analyst Ed Arce maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) yesterday and set a price target of $7.50. The company's shares closed last Monday at $0.80, close to its 52-week low of $0.76. According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.0% and a 39.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals. Currently, the analyst consensus on Cidara Therapeutics is a Strong Buy with an average price target of $6.75, a 738.5% upside from current levels. |
FDA Clears Cidara Therapeutics'' Phase 1 Trial For Immunotherapeutic Antiviral For InfluenzaThe FDA has signed off Cidara Therapeutics Inc'' s (NASDAQ: CDTX ) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company. Cidara Full story available on Benzinga.com |
Cidara announces FDA acceptance of its request to study the flu candidateCidara Therapeutics (CDTX) is trading ~3% higher in the pre-market on Monday after the company announced that the FDA accepted its Investigational New Drug ((IND)) application for the… |
FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For InfluenzaThe FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company. Cidara intends to initiate a Phase 1 study in healthy volunteers before the end of the current quarter. Related: Cidara Therapeutics Stock Slides Despite Acin |
CDTX Price Returns
| 1-mo | -41.91% |
| 3-mo | -36.07% |
| 6-mo | -69.39% |
| 1-year | -77.61% |
| 3-year | -76.56% |
| 5-year | -93.33% |
| YTD | -64.57% |
| 2021 | -36.50% |
| 2020 | -47.92% |
| 2019 | 63.40% |
| 2018 | -65.44% |
| 2017 | -34.62% |
Loading social stream, please wait...